Affiris gets grant for cholesterol vaccine
Vienna, Austria-based Affiris' atherosclerosis vaccine development program is to receive financial support from Eurotrans-Bio call. The supported project is based on the Affiris' Affitome technology and is being conducted in partnership with EMC microcollections from Tubingen, Germany.
The main item of the joint efforts of Affiris and EMC is the vaccination against cholesteryl ester transfer protein (CETP). By transferring cholesteryl ester from high-density lipoprotein cholesterol to low-density, this protein reduces "good" HDL and has a detrimental impact on the ratio of LDLc to HDLc.
The CETP Vaccine project is scheduled to last 30 months and is due to culminate in Phase I clinical trials. Overall, the support provided to the project by the EU is worth several hundred thousand euros, while the two project partners are bearing around half of the total costs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze